Open Innovation or Traditional Patenting Strategies to Efficiently Address Health Emergencies? How Patent Information Was Used Towards Effective Treatments for COVID-19.

Q3 Biochemistry, Genetics and Molecular Biology
Tatiana Duque Martins Ertner de Almeida, Diéricon Sousa Cordeiro
{"title":"Open Innovation or Traditional Patenting Strategies to Efficiently Address Health Emergencies? How Patent Information Was Used Towards Effective Treatments for COVID-19.","authors":"Tatiana Duque Martins Ertner de Almeida, Diéricon Sousa Cordeiro","doi":"10.2174/0118722083303431240528041945","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction/objective: </strong>During the 1150 days of COVID-19 pandemic there were great efforts to develop efficient treatments for the disease. After this long time, some drugs emerged as treatment for COVID-19. Some of them are new drugs, most of them, known drugs. These developments were triggered by information already available in patent documents. Pharmaceutical companies, therefore, rushed to conduct drugs evaluations and trials in order to deliver to the world a reasonable treatment that could reach the majority of its population. However, it is not immediately clear how companies operated to reach their goals. The ability of open innovation to achieve results assertively and faster than closed innovation strategies is questioned and therefore, it is questioned whether pharmaceutical companies use open innovation to face COVID-19.</p><p><strong>Methods: </strong>In this work, data available on patent databases were mined to inform about the scientific and technological panorama of selected drugs tested for COVID-19 treatment and to understand the perspectives of such developments during the pandemic.</p><p><strong>Results: </strong>This study evidenced that most treatments were based on known drugs, that some of the initially promising drugs were abandoned during the pandemic, and that it was able to inform if open innovation and collaborations were explored strategies.</p><p><strong>Conclusion: </strong>This study evidenced that the developments during COVID-19 were not based on open innovation by revealing a patent race towards the treatment development, but with practically no collaborations or information exchange between companies, universities, and research facilities.</p>","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent patents on biotechnology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0118722083303431240528041945","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction/objective: During the 1150 days of COVID-19 pandemic there were great efforts to develop efficient treatments for the disease. After this long time, some drugs emerged as treatment for COVID-19. Some of them are new drugs, most of them, known drugs. These developments were triggered by information already available in patent documents. Pharmaceutical companies, therefore, rushed to conduct drugs evaluations and trials in order to deliver to the world a reasonable treatment that could reach the majority of its population. However, it is not immediately clear how companies operated to reach their goals. The ability of open innovation to achieve results assertively and faster than closed innovation strategies is questioned and therefore, it is questioned whether pharmaceutical companies use open innovation to face COVID-19.

Methods: In this work, data available on patent databases were mined to inform about the scientific and technological panorama of selected drugs tested for COVID-19 treatment and to understand the perspectives of such developments during the pandemic.

Results: This study evidenced that most treatments were based on known drugs, that some of the initially promising drugs were abandoned during the pandemic, and that it was able to inform if open innovation and collaborations were explored strategies.

Conclusion: This study evidenced that the developments during COVID-19 were not based on open innovation by revealing a patent race towards the treatment development, but with practically no collaborations or information exchange between companies, universities, and research facilities.

采用开放式创新还是传统专利战略来有效解决突发卫生事件?如何利用专利信息有效治疗 COVID-19。
导言/目标:在 COVID-19 大流行的 1150 天里,人们一直在努力开发该疾病的有效治疗方法。经过这么长时间的努力,出现了一些治疗 COVID-19 的药物。其中一些是新药,大多数是已知药物。这些药物的研发是由专利文件中已有的信息引发的。因此,制药公司急忙进行药物评估和试验,以便向全世界提供一种能够惠及大多数人的合理治疗方法。然而,人们并不清楚公司是如何运作以实现其目标的。与封闭式创新战略相比,开放式创新能否自信而快速地取得成果受到质疑,因此,制药公司是否利用开放式创新来面对 COVID-19 也受到质疑:在这项工作中,对专利数据库中的数据进行了挖掘,以了解用于 COVID-19 治疗的选定试验药物的科技全景,并了解在大流行期间此类发展的前景:结果:这项研究表明,大多数治疗方法都是基于已知药物,一些最初很有前景的药物在大流行期间被放弃了,而且它还能说明开放式创新和合作是否是探索的战略:这项研究表明,COVID-19 期间的发展并非基于开放式创新,它揭示了治疗方法开发中的专利竞赛,但公司、大学和研究机构之间几乎没有合作或信息交流。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Recent patents on biotechnology
Recent patents on biotechnology Biochemistry, Genetics and Molecular Biology-Biotechnology
CiteScore
2.90
自引率
0.00%
发文量
51
期刊介绍: Recent Patents on Biotechnology publishes review articles by experts on recent patents on biotechnology. A selection of important and recent patents on biotechnology is also included in the journal. The journal is essential reading for all researchers involved in all fields of biotechnology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信